Joseph G. Jurcic, MD

Specialties:
Cancer Care, Hematology, Medical Oncology

More specialties
Accepting New Patients

Virtual Visits/Telehealth

Profile Navigation

Overview
Schedule an Appointment
Location(s)
Insurance Accepted
Credentials & Experience
Research

Overview

Dr. Joseph Jurcic is Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. His main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease.
He is the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. He is author or coauthor of more than 80 articles and book chapters, has been the principal investigator on over 25 clinical trials, and regularly lectures at national and international meetings. He serves as a Leukemia Section Editor for The Oncologist. Prior to joining the faculty at Columbia University Medical Center, he was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years.

Areas of Expertise / Conditions Treated

Acute Leukemia
Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Aplastic Anemia
Chronic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
CMML (Chronic Myelomonocytic Leukemia)
Essential Thrombocythemia
Hairy Cell Leukemia
Hematologic Malignancy
Hemolytic Anemia
Immune Thrombocytopenia
Large Granular Lymphocytic Leukemia
Leukemia
Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Myeloproliferative Disease
Polycythemia Vera
Rare Diseases & Myeloproliferative Neoplasm

Academic Appointments

Professor of Medicine at CUMC

Administrative Titles

Director, Hematologic Malignancies Section

Hospital Affiliations

NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Schedule Virtual Visit

Phone Appointments

New and Existing Patients: (212) 305-5098

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.
Connect Sign In

Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue

New York, NY 10032



Phone: (212) 305-5098


Fax: (212)305-8112



Open location in Google Maps

Insurance Accepted

Aetna

Aetna Signature Administrators
EPO
HMO
Medicare Managed Care
NYP Employee Plan
NY Signature
POS
PPO
Student Health

Affinity Health Plan

Essential Plan
Medicaid Managed Care

AgeWell

Medicare Managed Care
Special Needs

Amida Care

Special Needs

Cigna

EPO
Great West (National)
HMO
POS
PPO

Emblem/GHI

Medicare Managed Care
PPO

Emblem/HIP

ConnectiCare
EPO
Essential Plan
HMO
Medicaid Managed Care
Medicare Managed Care
POS
PPO
Select Care (Exchange)
Vytra

Empire Blue Cross/Blue Shield

EPO
HMO
Medicare Managed Care
PPO

Empire Blue Cross Blue Shield HealthPlus

Child/Family Health Plus
Essential Plan
Medicaid Managed Care

Fidelis Care

Child/Family Health Plus
Essential Plan
Medicaid Managed Care
Medicare Managed Care

Healthfirst

Child/Family Health Plus
Leaf (Exchange)
Medicaid Managed Care
Medicare Managed Care

Local 1199

Local 1199

MagnaCare (National)

MagnaCare

Medicare

Railroad
Traditional Medicare

Multiplan

Multiplan

MVP Health Care

Child/Family Health Plus
Essential Plan
HMO
Medicaid Managed Care

Oxford Health Plans

Freedom
Liberty

RiverSpring

Special Needs

UnitedHealthcare

Compass (Exchange)
Empire Plan
HMO
Medicaid (Community Plan)
Medicare Managed Care
POS
PPO

VNSNY CHOICE

Medicare Managed Care
SelectHealth
Special Needs

WellCare

Medicaid Managed Care
Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

MD, University of Pennsylvania School of Medicine
1988 University of Pennslyvania School of Medicine
Internship: Barnes Jewish Hospital
Residency: Barnes Jewish Hospital
Fellowship: Memorial Sloan-Kettering Cancer Center

Board Certifications

Hematology
Medical Oncology

Honors & Awards

New York Magazine: Top Doctors Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2014, 2013, 2012, 2011, 2010
Top Doctors: New York Metro Area Castle Connolly, 2015, 2014, 2013, 2011, 2010, 2009, 2007
America's Top Doctors for Cancer Castle Connolly, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007
Louise and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research Memorial Sloan-Kettering Cancer Center, 2001
Super Doctor SuperDoctors.com



America's Top Doctor


NY Top Doctor

Research

Selected Publications

Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98:2651-2656.
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud ?…M, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.
Aliff TB, Maslak PB, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-1032.
Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg DA, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17:314-318.
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas K, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32:549-556.
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JG, Brown R, Ehmann WC, Schulman P, Frankel SR, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23:4110-4116.
Lamanna N, Jurcic JG, Noy A, Maslak PM, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde D, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high quality responses: Molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491-497.
Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymph 2009; 50:1336-1344.
Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss MA, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116:171-179.
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas K, Weiss MA, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16:5303-5311.
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254.
Brentjens R, Riviere I, Park JH, Davila ML, Want X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias. Blood 2011; 118:4817-4828.
Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers LE, Jurcic JG. Randomized, phase 2b study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated AML. Haematologica 2013 98:119-128.
Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina HR, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MRM, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Yahalom J, Heller G, Perales M-A. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphocytic leukemia in 1^st complete remission: long-term survival with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19:208-213.
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 20 March 2013; 5(177):177ra38.
Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram S, Orsini J, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, DeBlasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan H, Rowe JM, Douer D, Tallman MS. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37:1004-1009.Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126-31.


For a complete list of publications, please visit PubMed.gov